Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting a candidate antigen for inclusion in a vaccine using a biological response machine learning model. In one aspect, a method comprises receiving immunization history data for a subject, receiving viral strain data, using a biological response machine learning model to generate a predicted biological response score characterizing a predicted biological response of the subject having the immunization history to being exposed to the viral strain, and outputting the predicted biological response score.
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting a candidate antigen for inclusion in a vaccine using a biological response machine learning model. In one aspect, a method comprises obtaining data comprising a set of immunization histories and a set of viral strains, generating a plurality of predicted biological response scores using a biological response machine learning model, and selecting a candidate antigen for inclusion in a vaccine based at least in part on the plurality of predicted biological response scores.
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The present disclosure provides an in vitro system comprising a plurality of isolated human muscle cells and a plurality of lipid-nanoparticle (LNP)-encapsulated messenger RNA (mRNA), and methods of screening LNP-encapsulated mRNA for polypeptide expression with said system.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A system for designing vaccines includes one or more processors, and computer storage storing executable computer instructions in which, when executed by the one or more processers, cause the one or more processors to perform one or more operations. The one or more operations include applying, to a first temporal sequence data set, a plurality of driver models configured to generate output data representing one or more molecular sequences. The one or more operations include, for each of the plurality of driver models, training the driver model. The one or more operations include selecting, based on one or more trained translational responses, a set of trained driver models of the plurality of driver models. The one or more operations include selecting, based on second translational response data, a subset of trained driver models of the set of trained driver models.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61K 39/00 - Medicinal preparations containing antigens or antibodies
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory and inflammatory diseases and disorders; Vaccines for human use
The present disclosure relates to a process for preparing a compound of formula (7), comprising the step of reacting a compound of formula (6) with a reducing agent, and to process for preparing deoxycholic acid or a pharmaceutically acceptable salt thereof comprising said step, and to uses of the deoxycholic acid or a pharmaceutically acceptable salt thereof prepared by the process to extract outer membrane vesicles from Gram-negative bacteria.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; Antibodies for medical purposes; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; Vaccines for human use
20.
Protein-Saccharide Conjugation with Sodium Cyanoborohydride
Methods and uses of conjugating saccharides to protein carriers are disclosed herein. Exemplary conjugates prepared according to those methods and uses are also disclosed. Additionally, methods for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent are disclosed herein. Vaccine compositions as well as related methods and uses are also disclosed herein.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, pharmaceutical preparations for use in inflammatory, antibodies for medical use; pharmaceutical product for the prevention and treatment of respiratory diseases and disorders, vaccines for human use
23.
COMPOSITIONS AND METHODS FOR CIRCULAR RNA AFFINITY PURIFICATION
The present disclosure provides for circular RNA (circRNA) compositions and methods purification and use of the same. In particular, the disclosure relates to compositions and methods of making and using circRNA comprising one or more aptamers which specifically bind an affinity ligand.
This application relates to modified RNA polymerases, compositions or kits comprising the same, and methods of using the same, in particular, in the preparation of ribonucleic acids (RNAs), such as messenger RNAs (mRNAs), in in vitro transcription reactions.
A discrete-data object is received and may include a plurality of first discrete values, the discrete-data object may include one or more amino acid sequences. The discrete-data object is converted into a continuous-data object that may include a plurality of first continuous values. To the continuous-data object, a continuous-data algorithm is applied to generate a continuous-result object that may include a plurality of second continuous values. The continuous-result object is converted into a discrete-result object which may include a plurality of second discrete values. A vaccine is manufactured which may include at least one of the group that may include i) a protein defined by the discrete-result object, ii) a nucleic acid capable of producing the protein defined by the discrete-result object, and iii) a delivery vehicle capable of producing the protein defined by the discrete-result object.
One or more data objects are received defining a plurality of wild-type amino acid sequences. From the one or more data objects, a plurality of reduced-dimension sequences are generated in a reduced-dimension space. A plurality of candidate sequences are generated in the reduced-dimension space using the plurality of reduced-dimension sequences. One or more data objects defining a viral amino acid sequence are received. Viral sequences in the reduced-dimension space are received. As input to a titer-predictor, each of the candidate sequences and at least one of the reduced-dimension viral sequences are provided. As output from the titer-predictor, a candidate-score for each of the candidate sequences is received. At least one candidate sequence from among the candidate sequences are selected. At least one new amino acid sequence is generated. Each of the generated amino acid sequences is suitable for manufacturing a respective vaccine.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Provided herein is a nucleic acid (e.g., messenger RNA) vaccine encoding at least one antigenic prokaryotic polypeptide linked to one or both of a viral secretion signal peptide and a transmembrane domain. Also provided are methods of vaccination against a prokaryotic infection with the nucleic acid described herein.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
29.
HPLC-BASED ASSAYS FOR DETECTING MULTIPLE MRNA CONSTRUCTS
The disclosure relates to methods for detecting at least a first mRNA and a second mRNA or two or more mRNAs in a multi-mRNA composition using reverse-phase high pressure liquid chromatography (RP-HPLC). The methods are particularly suitable for analyzing multi- mRNA compositions comprising first and second mRNAs or two or more mRNAs of similar lengths. The disclosed methods also find utility in assessing the quality and/or integrity of each of the at least first and second mRNAs or two or more mRNAs in a multi-mRNA composition. In addition, the disclosed methods can be used to calculate the proportion of each mRNA in a multi-mRNA composition.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals, namely, pharmaceutical preparations for use in immunology, antibodies for medical use; Pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders, vaccines for human use
The disclosure relates to lipidic compounds of formula (I): A—(CH2)n—CX—B—Z—R1 (I) wherein R1 represents a lipophilic or hydrophobic tail-group, wherein RI is an optionally substituted, branched, saturated or unsaturated, C10 to C55 hydrocarbon radical, and which hydrocarbon skeleton that is optionally interrupted by one or several atoms of oxygen or nitrogen and/or one or several moiety —(C═O)—, —O—(C═O)— or —(C═O)—O— and which one nitrogen atom, if present in the skeleton, can be linked, directly or not, to said Z radical; Z is a spacer arm; B represents O or NH; X is O or S; n is 0, 1, 2, 3, 4, 5 or 6; and A represents (i) R2R3N-, (ii) NR2R3-Alk-Y-in which Y is O or N, Alk is an alkylene moiety in C2 to C6 and R2 and R3 represent independently of each other a linear or branched (C1-C6) alkyl group, or (iii) a 4- to 8-membered saturated heterocyclic radical comprising 3 to 7 carbon atoms and 1 or 2 nitrogen atoms, said 4- to 8-membered saturated heterocyclic radical being linked to the rest of the molecule by a carbon atom or a nitrogen atom and being optionally substituted by 1 to 4 substituents, independently of each other, selected from a linear or branched (C1-C6) alkyl group; or one of its pharmaceutically acceptable salts thereof; and with said compound that is in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.
Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.
This application relates to modified influenza B hemagglutinin polypeptides and nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and/or treatment of diseases or conditions caused by influenza B viruses.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
The present disclosure provides a Lyme disease vaccine, comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one bacteria of the genus Borrelia, and methods of eliciting an immune response by administering said vaccine.
The present disclosure provides compositions comprising at least two messenger RNAs (mRNAs) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and/or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen, and methods of eliciting an immune response by administering said compositions.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE (USA)
Inventor
Chan, Yvonne
Sasmal, Sukanya
Stuebler, Antonia
Kishko, Michael
Mundle, Sophia
Zhang, Linong
Dinapoli, Josh
Alamares-Sapuay, Judith
Anosova, Natalie
Chivukula, Sudha
Danz, Hillary
Strugnell, Tod
Groppo, Rachel
Collins, Peter
Buchholz, Ursula
Munir, Shirin
Dahal, Bibha
Abstract
The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.
The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.
The present invention relates to a method for freezing or freeze-drying lipid nanoparticles (LNPs) comprising at least a nucleic acid and, at least, as lipid components, a cationic ionizable lipid, a neutral lipid, and a steroid alcohol, or an ester thereof. The method comprises the steps of providing a liquid composition comprising said LNPs, spraying the composition of step a) in conditions suitable for obtaining liquid droplets, and freezing the liquid droplets obtained at step b) to obtain frozen LNPs. The method may also comprise a step of drying the frozen LNPs obtained to obtain freeze-dried LNPs. The invention also relates to frozen and freeze-dried LNPs.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
73.
SYSTEMS AND DEVICES FOR FILTERING BIOLOGICAL PRODUCTS AND METHODS OF USING THE SAME
Systems and devices for filtering biological products and methods of using the same are provided. A filtration system can include a filtration skid configured to be adapted for engagement with components of a single-use assembly for facilitating one or more unit operations of a continuous filtering process for the one or more biological products. The filtration skid can include a pump cart and a filtration cart. The filtration cart can include a first filter support assembly configured to support a first filtering flow channel and a second filter support assembly configured to support a second filtering flow channel.
A dose divider for releasable attachment to a plunger rod of a syringe comprises first and second arms. A front portion of the first arm and the front portion of the second arm form a channel therebetween for receiving the plunger rod. A resilient hinge pivotably couples the first arm and the second arm such that the dose divider is reversibly movable between first and second configurations. When the dose divider is in the second configuration, the dose divider is configured to receive the plunger rod in the channel through an opening formed between the front portions of the first and second arms. The channel has a shape configured to receive a specific outer shape of the plunger rod. The front portions of the first and second arms are closer when the dose divider is in the first configuration than when the dose divider is in the second configuration.
A61M 15/08 - Inhaling devices inserted into the nose
B05B 11/02 - Membranes or pistons acting on the contents inside the container, e.g. follower pistons
F16B 2/22 - Clips, i.e. with gripping action effected solely by the inherent resistance to deformation of the material of the fastening of resilient material, e.g. rubbery material
This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.
A medicament delivery system comprises a syringe and a plunger rod. The plunger rod comprises a first region of a first outer configuration and a second region of a second outer configuration that is different to the first outer configuration. A blocking element is configured to be provided at a proximal end of the syringe and disposed around the plunger rod, and which permits the plunger rod to move over a first range of motion relative to the syringe to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe to expel further medicament. The blocking element is configured to be removable from the plunger rod. The plunger rod is free to move over the subsequent range of motion relative to the syringe to expel further medicament once the blocking element is removed from the plunger rod.
A delivery system comprises a syringe having a chamber for containing medicament and an outlet through which medicament can be expelled. A plunger rod is moveable relative to the syringe and configured to cause medicament to be expelled from the syringe when medicament is within the syringe and the plunger rod is moved. A disc, when the delivery system is in a first configuration, permits the plunger rod to move over a first range of motion relative to the syringe to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe to expel further medicament. The disc or the plunger rod is rotatable to put the delivery system into a second configuration, in which the plunger rod is free to move over the subsequent range of motion relative to the syringe to expel further medicament
A method of using a dose divider comprising first and second arms, each having a front portion that together form a channel for receiving a syringe plunger rod. A resilient hinge pivotably couples the first and second arms such that the dose divider is reversibly movable between first and second configurations. In the second configuration, the dose divider is configured to receive the plunger rod in the channel formed between the front portions of the first and second arms. The channel is configured to receive a specific outer shape of the plunger rod. The front portions of the first and second arms are closer when the dose divider is in the first configuration than when in the second configuration. The method comprises moving the dose divider from the first configuration to the second configuration by applying a force to the first and second arms such that the first arm pivots in a first direction with respect to the second arm using the resilient hinge.
A medicament delivery system comprises a syringe, a plunger rod is, and a guide element at a proximal end of the syringe and comprising an aperture through which the plunger rod extends. The guide element and the plunger rod are relatively rotatable between blocking and release positions. A guide mechanism provided on the plunger rod and the guide element permits the plunger rod to move axially over a first range of motion relative to the syringe from an initial position to an intermediate position to expel a first dose of medicament, and blocks the plunger rod from moving over a subsequent range of motion relative to the syringe. The plunger rod is free to move in an axial direction over the subsequent range of motion to expel further medicament upon relative rotation of the guide element and the plunger rod from the blocking position to the release position.
Provided are modified influenza virus subtype 2 neuraminidase molecules lacking all or substantially all of the stalk region that form active, soluble tetrameric neuraminidase when expressed in host cells and vaccine compositions comprising the tetrameric neuraminidase or a nucleic acid encoding the modified monomeric influenza virus subtype 2 neuraminidase molecules that forms tetrameric NA when expressed in a cell. Also provided are methods of using the vaccine compositions to vaccinate or immunize a subject against influenza virus.
The present disclosure provides methods and compositions for RNA affinity purification. In particular, the disclosure relates to compositions and methods of making and using mRNA comprising one or more aptamers which specifically bind an affinity ligand.
Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.
Provided are novel vaccines for prophylactic treatment of SARS-COV-2 infections and COVID-19 and methods of making the vaccines, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene.
Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.
Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, namely, pharmaceutical preparations for use in immunology; antibodies for medical use; pharmaceutical preparations for the prevention and treatment of respiratory and inflammatory diseases and disorders; vaccines for human use
